CN105348223A - Novel sesquiterpenoid and preparation method and medical application thereof - Google Patents
Novel sesquiterpenoid and preparation method and medical application thereof Download PDFInfo
- Publication number
- CN105348223A CN105348223A CN201510887739.3A CN201510887739A CN105348223A CN 105348223 A CN105348223 A CN 105348223A CN 201510887739 A CN201510887739 A CN 201510887739A CN 105348223 A CN105348223 A CN 105348223A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- extract
- cell
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D301/00—Preparation of oxiranes
- C07D301/32—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/32—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
Abstract
The invention discloses a novel sesquiterpenoid and a preparation method and medical application thereof, and belongs to the technical field of medicines. The novel sesquiterpenoid is reported for the first time, is novel in structure and can be obtained by extraction, separation and purification of dry leaves of psidium guajava Linn. Researches show that the novel sesquiterpenoid can induce remarkable cycle arrest and apoptosis after acting on Mol4 and enable the cell cycle to remain in the S phase so as to induce apoptosis and inhibit cell proliferation. The novel sesquiterpenoid (I) has a potential application value in treating acute T lymphoblastic leukemia, and can be used for developing medicines for treating acute T lymphoblastic leukemia.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to from the dry leave of piscidia, be separated obtain a kind of and there is sesquiterpenoids for the treatment of Pancytopenia effect and preparation method thereof.
Background technology
Plant piscidia (PsidiumguajavaLinn.) is Myrtaceae (Myrtaceae) Psidium plant, is deciduous tree, high 5-10m.Bark light tan, spray square, tool white undercoat, then comes off always; Bud is close by white undercoat.Single leaf alternate, rare verticillate, square round shape is oval to oval, long 5-12cm, wide 3-5cm, that rubs has fragrance, keratin, tip circle or short point, base portion is blunt to circular, Quan Yuan, above deep green, vein nick or smooth, dredges raw undercoat time tender, below light green, dredge raw glandula, close by pubescence, master pulse swells, lateral vein 7-11 couple, also swells, and nearly tiltedly goes out leaf margin and bends; Cry handle long 4mm.Flower both sexes, the raw 1-4 piece of armpit; Calyx 5, green, oval; Petal white, avette, long 2-2.5cm; Stamen is most, isometric with petal, filigree white, and flower pesticide is light yellow, lobe; Gynoecium 1, style is longer than filigree, and column cap is circular, and ovary is the next, Room 3, and ovule is most.Berry is spherical, oval or foreign pears shape, and long 2.5-8cm, footpath 3-5cm, pulp is usually yellow, also adularescent or kermes.Seed oval, pale.The florescence 5-8 month.The fruit phase 8-11 month.Guava Leaf is dry leave and the band leaf spray of piscidia, and another name chicken vows tea, kind peach leaf, that pulls out leaf etc.Guava Leaf is flat, sweet-puckery flavor, and entering spleen, stomach, large intestine, Liver Channel, have drying damp and strengthening spleen, clearing heat and detoxicating effect, is folk therapy diabetes, enteritis and dysentery, the common drug of wound hemorrhage.
Guava Leaf chemical composition is various, mainly comprises phenolic acids, flavonoid, triterpenes and sesquiterpenoids.In recent years, the sesquiterpenoids composition in Guava Leaf attracts wide attention because of its good biological activity.Sesquiterpenoids (sesquiterpenoids) is made up of 3 isoprene units, containing the compound monoid of 15 carbon atoms.Sesquiterpene is extensively present in plant, microorganism, marine organisms and some insect, much there is important biological function and physiologically active, particularly sesquiterpene lactones, there are antibacterial, antitumor, antiviral, cell toxicant, immunosuppression, vegetable poison, insect hormone, antifeedant for insect isoreactivity, also have some to have nervous system activity.
Summary of the invention
The object of this invention is to provide and a kind ofly from the dry leave of piscidia, be separated obtain a kind of there is sesquiterpenoids for the treatment of Pancytopenia effect and preparation method thereof.
Above-mentioned purpose of the present invention is achieved by technical scheme below:
There is the compound (I) of following structural formula,
The preparation method of described compound (I), comprise following operation steps: the dry leave of piscidia is pulverized by (a), extract with 80 ~ 90% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, then use 80% ethanol elution, 8 column volumes, collect 80% ethanol eluate, concentrating under reduced pressure obtains 80% ethanol elution thing medicinal extract; C in () step (b), 80% ethanol elution medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 80:1,50:1,35:1,15:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 25:1,15:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 75%, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
Further, described macroporous resin is AB-8 type macroporous adsorbent resin.
Further, described alcohol heat reflux extracts the alcohol concn adopted is 85%.
A kind of pharmaceutical composition, the described compound (I) wherein containing treatment significant quantity and pharmaceutically acceptable carrier.
The application of described compound (I) in the medicine of preparation treatment Pancytopenia.
The application of described pharmaceutical composition in the medicine of preparation treatment Pancytopenia.
When the compounds of this invention is used as medicine, directly can uses, or use with the form of pharmaceutical composition.
This pharmaceutical composition contains the compounds of this invention (I) for the treatment of significant quantity, and all the other are acceptable on pharmacology, nontoxic to humans and animals and pharmaceutically acceptable carrier of inertia and/or vehicle.
Described pharmaceutically acceptable carrier or vehicle are that one or more are selected from solid, semisolid and liquid diluent, filler and pharmaceutical preparation assistant agent.Pharmaceutical composition of the present invention is used with the form of per weight dose.Medicine of the present invention is applied to by form that is oral or injection the patient needing treatment.For time oral, tablet, slow releasing tablet, controlled release tablet, capsule, dripping pill, micropill, suspensoid, emulsion, powder or granule, oral liquid etc. can be made into; During for injecting, can be made into water-based or oily solution, aseptic powder injection, liposome or the emulsion etc. of sterilizing.
Accompanying drawing explanation
Fig. 1 is compound (I) structural formula;
Fig. 2 is that the theoretical ECD value of compound (I) compares with experiment ECD value.
Embodiment
Further illustrate essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.Although be explained in detail the present invention with reference to preferred embodiment, those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the scope of technical solution of the present invention.
Embodiment 1: compound (I) is separated preparation and structural identification
Reagent source: ethanol, sherwood oil, ethyl acetate, propyl carbinol, methylene dichloride are analytical pure, purchased from Shanghai Ling Feng chemical reagent company limited, methyl alcohol, analytical pure, purchased from Jiangsu Han Bang chemical reagent company limited.
Preparation method: the dry leave (8kg) of piscidia is pulverized by (a), (25L × 3 time) are extracted with 85% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste (3L), use sherwood oil (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated propyl carbinol (3L × 3 time) to extract successively, obtain petroleum ether extract, acetic acid ethyl ester extract (359g) and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract AB-8 type macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, use 80% ethanol elution, 8 column volumes again, collect 80% ethanol eluate, concentrating under reduced pressure obtains 80% ethanol elution thing medicinal extract (138g); C in () step (b), 80% ethanol elution medicinal extract purification on normal-phase silica gel is separated, successively with volume ratio be 80:1 (8 column volumes), the methylene chloride-methanol gradient elution of 50:1 (8 column volumes), 35:1 (6 column volumes), 15:1 (8 column volumes) and 1:1 (5 column volumes) obtains 5 components; D component 4 (32g) is separated further by purification on normal-phase silica gel in () step (c), successively with volume ratio be 25:1 (8 column volumes), the methylene chloride-methanol gradient elution of 15:1 (10 column volumes) and 5:1 (6 column volumes) obtains 3 components; E in () step (d), component 2 (17g) reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 75%, collect 8-10 column volume elutriant, elutriant concentrating under reduced pressure obtains pure compound (I) (229mg).
Structural identification: colorless oil; HR-ESIMS shows [M+Na]
+for m/z257.1524, can obtain molecular formula in conjunction with nuclear-magnetism feature is C
15h
22o
2, degree of unsaturation is 5.Hydrogen nuclear magnetic resonance modal data δ
h(ppm, DMSO-d
6, 600MHz): H-2 (2.27, m), H-2 (2.02, m), and H-4 (2.28, s), H-6 (1.96, d, J=10.8), and H-7 (2.14, m), H-8 (1.39, m), H-8 (1.28, m), H-9 (1.68, m), H-9 (1.37, m), and H-10 (2.45, m), H-12 (4.57, s), H-12 (4.64, s), and H-13 (1.65, s), H-14 (1.07, d, J=7.1), H-15 (1.21, d, J=7.0); Carbon-13 nmr spectra data δ
c(ppm, DMSO-d
6, 150MHz): 51.7 (C, 1-C), 42.6 (CH
2, 2-C), 218.1 (C, 3-C), 55.5 (CH, 4-C), 61.8 (C, 5-C), 32.5 (CH
2, 6-C), 42.3 (CH, 7-C), 28.5 (CH
2, 8-C), 31.1 (CH
2, 9-C), 30.4 (CH, 10-C), 151.2 (C, 11-C), 108.1 (CH
2, 12-C), 20.4 (CH
3, 13-C), 18.6 (CH
3, 14-C), 17.1 (CH
3, 15-C); Carbon atom mark is see Fig. 1.
1hNMR composes display three methyl [δ H1.65 (3H, s, H-13), 1.07 (3H, d, J=7.1Hz, H-14) and 1.21 (3H, d, J=7.0Hz, H-15)], and terminal double link δ H4.57 (1H, s, H-12a) and 4.64 (1H, s, H-12b).
13cNMR composes display 15 resonance carbon signal, comprise three methyl, five methylene radical [olefinic methylene radical δ C108.1 (C-12)], [two containing oxygen quaternary carbon δ C51.7 (C-1) and 61.8 (C-5) for three methynes and four quaternary carbons, ketone carbonyl δ C218.1 (C-3), alkene quaternary carbon δ C151.2 (C-11)].Containing oxygen carbon signal δ C51.7 (C-1) and 61.8 (C-5), two show that this compound contains 1, a 5-epoxide group.Two alkene carbon signals [δ C108.1 (C-12) and 151.2 (C-11)], and two terminal ethylenic proton signal [δ H4.57 (s, H-12) and 4.64 (s, H-12)] show that this compound contains one two and replaces double bond.In ROESY spectrum, H-10 and H-7, H-2 β and Me-14 and Me-15, Me-15 and H-8 β and H-9 β, the dependency of H-8 β and Me-13 shows H-4, H-7 and H-10 is α configuration, Me-14 and Me-15 is beta comfiguration.Comprehensive hydrogen spectrum, carbon spectrum, HMBC spectrum and ROESY spectrum, and document is about correlation type nuclear magnetic data, can substantially determine this compound as shown in Figure 1, steric configuration is determined further by ECD test, theoretical value and experimental value basically identical (Fig. 2).
Embodiment 2: compound (I) pharmacological action is tested
One, material and instrument
Pancytopenia Molt4 cell is so kind as to give by hemopathy institute of Ji'nan University; Chronic myeloid leukemia cell K562 cell is so kind as to give by Biochemistry and Molecular Biology teaching and research room by Ji'nan University.Compound (I) is self-control, and HPLC normalization method purity is greater than 98%, dissolves be mixed with 5.5 μ g/mL solution for standby with DMSO analytical pure.DMEM/F12 medium powder, hydroxyethyl piperazine ethanesulfonic acid (HEPES), the blue reagent of tetraphenyl nitrogen (MTT) are purchased from Gibeo company of the U.S..New-born calf serum (NewbomCalfSerum) is purchased from Hangzhou China folium ilicis chinensis company.Penicillin (Penicillin), Streptomycin sulphate (Streptomycin) are purchased from China of North China drugmaker.Iodate third eyelash (PT) is purchased from Sigma Co., USA.The two transfection reagent box of PI-AnnexinV is purchased from Bao Sai biotech company of BeiJing, China.ROS high-quality fluorimetric reagent box is purchased from Chinese green skies biotechnology research institute.Rhodamine123 is purchased from MolecularProbes company of the U.S..
CO
2incubator (U.S. ThermoForma), Bechtop (Chinese Suzhou purifying apparatus factory), pressure steam sterilization boiler (LDZX40BI) (Chinese Shanghai Shen An medical apparatus and instruments factory), TGL-16G type table model high speed centrifuge (Chinese Shanghai An Ting scientific instrument factory), MA260S type electronic analytical balance (Chinese Shanghai second balance equipment factory), automatic dual pure water distiller (Chinese Shanghai glassware one factory), SterivexTM, 0.22 μm of Millex Syringe Filters (Millipore company of the U.S.), XDS-1B optics inverted microscope (Chongqing in China optical instrument factory), full-automatic microplate reader (BIO-RID company of the U.S.), FACSCalibur flow cytometer (BDFACSAria company of the U.S.).QL-901 type vortex mixer (kylin medical apparatus factory of Jiangsu Haimen City).
Two, test method
1, cell cultures
People's Pancytopenia cell Molt4 cell culture system: DMEM/F12 nutrient solution containing 10% new-born calf serum, is put 37 DEG C, volume fraction is 5%CO
2incubator, every 2-3 days Secondary Culture.Select logarithmic phase, the cell of 0.2% trypan blue exclusion rate >95% tests.
2, mtt assay detects cell proliferation inhibition rate
3 × 10
4mLMolt4 cell is inoculated in 96 well culture plates, and final volume is 200 μ L/ holes, and often group establishes 5 multiple holes, and compound (I) establishes five concentration to be respectively 2.5 μ g/mL, 5 μ g/mL, 10 μ g/mL, 15 μ g//mL, 20 μ g//mL.Put 37 DEG C, 5%CO
2after cultivating 48h, 72h in incubator, every hole adds MTT solution (5mg/mL PBS<ph=7.4 joins) 20 μ L, continues to hatch 4 hours, stops cultivating, centrifugal, culture supernatant in hole is abandoned in careful suction, and every hole adds 150 μ LDMSO, vibrates 10 minutes, crystallisate is fully melted, microplate reader detects light absorption value (measuring wavelength 570nm, reference wavelength 690nm), calculates each group of proliferation inhibition rate.Each experiment repetition 3 times, gets its average.Proliferation inhibition rate (%)=(1-A experimental group/A control group) × 100%.
3, the mono-dye of PI detects the cell cycle
2 × l0
5/ mLMolt4 cell is inoculated in 12 well culture plates, every hole 1800 μ L, and compound (I) establishes three concentration to be respectively 5 μ g/mL, 10 μ g/mL15 μ g/mL, final volume 2500 μ L, if 3 multiple holes.Put 37 DEG C, 5%CO
2collecting cell after 48h is cultivated in incubator, the 0.01mol/LPBS washed cell of precooling 2 times, be that 70% ethanol 4 DEG C fixedly spends the night by volume fraction, centrifugally remove supernatant, add PI staining fluid (containing RNA enzyme), final concentration 50 μ g/mL, lucifuge dyeing 30min, flow cytometer analysis of cells DNA content after 300 order nylon net filters, each sample stochastic analysis 12000 cells, obtain each group of cell growth cycle ratio, U.S. BDFACSortCellQuest software analysis result.
4, the two dye of AnnexinV-PI measures apoptosis ratio
Cell process and adding method thereof are all the same, and after cultivating 48h, adjustment cell concn is 5 × 106/mL, get lmL cell for each group, precooling 0.01mol/LPBS washs 3 times, exhausts supernatant, adds the binding buffer liquid that 200 μ L test kits provide, re-suspended cell, add 10 μ LAnnexinV-FITC and 5 μ L respectively, mix gently, 4 DEG C of lucifuge reaction 30min, add 300 μ L binding buffer liquid again, flow cytomery.The cell mass (i.e. LR cell mass) of AnnexinV-FITC+, PI-is viable apoptotic cell.
5, statistical study
With mean scholar standard deviation
represent, the process of application SPSS13.0 statistical software, adopts the one-way analysis of variance (one-wayANOVA) of completely randomized design to analyze the significance of group difference.
Three, result and conclusion
1, compound (I) is to the inhibited proliferation of Molt4 cell
Compound (I) all has obvious inhibited proliferation in different time points to Molt4 cell.DMSO (0.5%) group is 5.2% ± 0.8%, 6.40% ± 0.9% at the proliferation inhibition rate of 48h, 72h respectively.The proliferation inhibition rate of different concns compound (I) treatment group all has statistical significance (P<0.01) compared with DMSO group.Under same concentrations condition, comparatively 48h is high for the proliferation inhibition rate of 72h.Compound (I) is to the IC of Molt4 cell 48h, 72h
5019.4 ± 0.2 μ g/mL, 15.7 ± 0.1 μ g/mL respectively.The compound (I) of different concns all shows certain proliferation inhibiting effect, and there is the time, dosage relies relation.The results are shown in Table for 1 (note: * mark compares with Control group, P<0.01).
2, compound (I) is on the impact of Molt4 cell cycle
After compound (I) effect Molt4 cell 48h, blank group G1 phase cell proportion is 37.5% ± 0.2%, S phase cell proportion is 50.6% ± 0.1%, G2 phase cell proportion is 11.7% ± 0.1%, DMSO group G1 phase cell proportion is 39.6% ± 0.1%, S phase cell proportion is 51.6% ± 0.2%, G2 phase cell proportion is 8.7% ± 0.2%.Shared by compound (I) medicine 20 μ g/mL, 25 μ g/mL treatment group G1 phases, cell proportion is respectively 4.1% ± 0.1%, 65.8% ± 0.1%, ratio increase shared by S phase cell is respectively 85.1% ± 0.3%, 87.1% ± 0.25 (P<0.01), G2 phase cell proportion is respectively 10.7% ± 0.2%, 7.0% ± 0.1%, the result display G1 phase have significant difference (P<0.05) to illustrate compound (I) retardance Molt4 cell is in the cycle S phase.The results are shown in Table for 2 (note: * mark compares with Control group, P<0.01).
3, the early apoptosis rate after compound (I) effect Molt4 cell
After compound (I) effect Molt4 cell 48h, AlmexinV/PI two dye flow cytomery early apoptosis rate.Early apoptosis rate 7.0% scholar 0.3% of blank group early apoptosis of cells rate 6.6% ± 0.4%, DMSO control group, not statistically significant (p>0.05) compared with blank.Compound (I) 10 μ g/mL group, 15 μ g/mL group early apoptosis rates are 9.5% ± 0.3%, 15.0% ± 0.5% respectively, have statistical significance (P<0.05) compared with blank.The results are shown in Table for 3 (note: * mark compares with Control group, P<0.05).
Conclusion, we can induce its significant Cycle Arrest and apoptosis after finding compound (I) effect Molt4 cell under study for action, and make cell cycle arrest in the S phase, thus cell death inducing, antiproliferative effect.Compound (I) has potential using value in treatment Pancytopenia.
Table 1 compound (I) to the inhibited proliferation of Molt4 cell (%,
n=3)
| Group | 48h inhibiting rate (%) | 72h inhibiting rate (%) |
| DMSO | 5.2±0.8 | 6.4±0.9 |
| Compound (I) 2.5 μ g/mL | 6.3±1.3 | 8.4±1.1 |
| Compound (I) 5 μ g/mL | 10.5±2.4 | 11.6±2.5 |
| Compound (I) 10 μ g/mL | 18.6±1.6 * | 26.9±2.7 * |
| Compound (I) 15 μ g/mL | 33.4±2.7 * | 49.4±2.2 * |
| Compound (I) 20 μ g/mL | 53.2±4.4 * | 65.4±1.6 * |
Table 2 each group cell cycle per-cent (%,
n=3)
Table 3 compound (I) on the apoptotic impact of Molt4 (%,
n=3)
| Group | Apoptosis rate |
| Control | 6.6±0.2 |
| DMSO | 7.0±0.4 |
| Compound (I) 10 μ g/mL | 9.5±0.3 * |
| Compound (I) 15 μ g/mL | 15.0±0.3 * |
Embodiment 3
The preparation of tablet: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, vehicle is added, pelletizing press sheet than the ratio for 1:9 in itself and excipient weight.
Embodiment 4
Prepared by oral liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, oral liquid method for making makes oral liquid routinely.
Embodiment 5
The preparation of capsule or granule: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, add vehicle in itself and excipient weight than the ratio for 1:9, make capsule or granule.
Embodiment 6
The preparation of injection liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, inject with water routinely, essence filter, injection liquid is made in embedding sterilizing.
Embodiment 7
The preparation of aseptic powder injection: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, be dissolved in sterile water for injection, stirring makes molten, filter with aseptic suction funnel, aseptic essence filter again, be sub-packed in ampoule, after frozen drying, aseptic sealing by fusing obtains powder injection.
The effect of above-described embodiment is essentiality content of the present invention is described, but does not limit protection scope of the present invention with this.Those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the protection domain of technical solution of the present invention.
Claims (7)
1. there is the compound (I) of following structural formula,
2. the preparation method of compound according to claim 1 (I), it is characterized in that comprising following operation steps: the dry leave of piscidia is pulverized by (a), extract with 80 ~ 90% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, then use 80% ethanol elution, 8 column volumes, collect 80% ethanol eluate, concentrating under reduced pressure obtains 80% ethanol elution thing medicinal extract; C in () step (b), 80% ethanol elution medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 80:1,50:1,35:1,15:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 25:1,15:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 75%, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
3. the preparation method of compound according to claim 2 (I), is characterized in that: described macroporous resin is AB-8 type macroporous adsorbent resin.
4. the preparation method of compound according to claim 2 (I), is characterized in that: it is 85% that described alcohol heat reflux extracts the alcohol concn adopted.
5. a pharmaceutical composition, is characterized in that: the compound according to claim 1 (I) wherein containing treatment significant quantity and pharmaceutically acceptable carrier.
6. the application of compound according to claim 1 (I) in the medicine of preparation treatment Pancytopenia.
7. the application of pharmaceutical composition according to claim 5 in the medicine of preparation treatment Pancytopenia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510887739.3A CN105348223A (en) | 2015-12-07 | 2015-12-07 | Novel sesquiterpenoid and preparation method and medical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510887739.3A CN105348223A (en) | 2015-12-07 | 2015-12-07 | Novel sesquiterpenoid and preparation method and medical application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105348223A true CN105348223A (en) | 2016-02-24 |
Family
ID=55324307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510887739.3A Withdrawn CN105348223A (en) | 2015-12-07 | 2015-12-07 | Novel sesquiterpenoid and preparation method and medical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105348223A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105418727A (en) * | 2016-01-12 | 2016-03-23 | 王尧尧 | Novel ursanes diterpenoid compound and preparation method and medical application thereof |
| CN105968082A (en) * | 2016-05-31 | 2016-09-28 | 黄芳 | Pharmaceutical composition of cysteine hydrochloride and medical application of pharmaceutical composition |
| CN107540641A (en) * | 2016-06-29 | 2018-01-05 | 彭朗 | A kind of new organic esterses and preparation method thereof and medical usage |
| CN114796319A (en) * | 2022-03-22 | 2022-07-29 | 山东第一医科大学(山东省医学科学院) | Preparation method and application of guava leaf extract |
-
2015
- 2015-12-07 CN CN201510887739.3A patent/CN105348223A/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105418727A (en) * | 2016-01-12 | 2016-03-23 | 王尧尧 | Novel ursanes diterpenoid compound and preparation method and medical application thereof |
| CN105968082A (en) * | 2016-05-31 | 2016-09-28 | 黄芳 | Pharmaceutical composition of cysteine hydrochloride and medical application of pharmaceutical composition |
| CN107540641A (en) * | 2016-06-29 | 2018-01-05 | 彭朗 | A kind of new organic esterses and preparation method thereof and medical usage |
| CN114796319A (en) * | 2022-03-22 | 2022-07-29 | 山东第一医科大学(山东省医学科学院) | Preparation method and application of guava leaf extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105153187A (en) | New diterpenoid as well as preparation method and medical application thereof | |
| CN105153269A (en) | New triterpene compounds, and preparation method and medical application thereof | |
| CN105348223A (en) | Novel sesquiterpenoid and preparation method and medical application thereof | |
| CN105085539A (en) | Novel diterpenoid compound, preparation method thereof and medical application | |
| CN105330717A (en) | Novel triterpenoid and preparation method and medical application thereof | |
| CN104974145A (en) | Diterpene lactone compounds, pharmaceutical composition containing compounds, and preparation method and application thereof | |
| CN105943532A (en) | Application of diterpenoid compound to preparation of medicament for treating liver cancer | |
| CN105085452A (en) | Sesquiterpene naphthoquinone compound as well as preparation method and medical application thereof | |
| CN105218489A (en) | A kind of assorted terpene compound newly and preparation method thereof and medicinal use | |
| CN105153086A (en) | Novel sesquiterpenoids compound and preparation method and medical application thereof | |
| CN105566427A (en) | Lanostane triterpene compound, and preparation method and medicinal use thereof | |
| CN105367536A (en) | Novel iridoid and preparation method and medical application thereof | |
| CN105524075A (en) | A novel diterpene compound, a preparing method thereof and medical uses of the diterpene compound | |
| CN105503896A (en) | New phloroglucin compounds, and preparation method and medical application thereof | |
| CN105294726A (en) | Novel flavanone compound, preparation method of novel flavanone compound and medical application of novel flavanone compound | |
| CN105418539A (en) | New meroterpenoid compound as well as preparation method and pharmaceutical application thereof | |
| CN105001230A (en) | Sesquiterpene compound, pharmaceutical composition containing sesquiterpene compound, and preparation method and applications of sesquiterpene compound | |
| CN105481876A (en) | Diterpene compound for treating ovarian cancer | |
| CN105503895A (en) | Novel diterpene compound for treating acute T lymphocytic leukemia | |
| CN105503996A (en) | Limonin compound as well as preparation method and neuroprotective effect thereof | |
| CN105254497A (en) | Novel diterpenoid compound and preparation method and medical application thereof | |
| CN105418727A (en) | Novel ursanes diterpenoid compound and preparation method and medical application thereof | |
| CN105418719A (en) | Lanostane triterpenoid for treating acute T-lymphocyte leukemia | |
| CN105418717A (en) | Steroid compound for treating leukemia and preparation method thereof | |
| CN106117034A (en) | A kind of highly oxidized sesquiterpenoids and preparation method thereof and medical usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160224 |